Veru (VERU) Research & Development (2016 - 2024)
Veru (VERU) posted quarterly Research & Development of $3.3 million for Q3 2024, down 16.5% year-over-year from $3.9 million in Q4 2023, and down 32.52% quarter-over-quarter from $4.9 million in Q2 2024.
Veru (VERU) Research & Development (2016 - 2024) Analysis & Trends
Veru (VERU) has reported Research & Development for 9 consecutive years, with $3.3 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Research & Development fell 16.5% year-over-year to $3.3 million; the TTM figure through Sep 2024 stood at $12.8 million (down 74.99% YoY), while the FY2024 annual figure was $12.8 million, down 74.99% from the prior year.
- Research & Development eased to $3.3 million in Q3 2024 per VERU's latest filing, from $4.9 million in the prior quarter.
- Across five years, Research & Development topped out at $27.2 million in Q3 2022 and bottomed at $1.7 million in Q4 2023.
- Historically, Research & Development has averaged $9.4 million across 5 years, with a median of $7.6 million in 2021.
- Annual changes were most pronounced in 2022 — Research & Development surged 228.93% — and 2023, when it plunged 91.99%.
- Veru's Research & Development stood at $5.7 million in 2020, then jumped by 77.56% to $10.1 million in 2021, then jumped by 104.45% to $20.6 million in 2022, then slumped by 91.99% to $1.7 million in 2023, then surged by 99.53% to $3.3 million in 2024.
- Business Quant data shows VERU's Research & Development at $3.3 million in Q3 2024, $4.9 million in Q2 2024, and $3.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Veru | 59.70 Mn | 33.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 3.29 Mn |
| Jun 30, 2024 | 4.88 Mn |
| Mar 31, 2024 | 2.99 Mn |
| Dec 31, 2023 | 1.65 Mn |
| Sep 30, 2023 | 3.94 Mn |
| Jun 30, 2023 | 8.79 Mn |
| Mar 31, 2023 | 17.86 Mn |
| Dec 31, 2022 | 20.61 Mn |
| Sep 30, 2022 | 27.16 Mn |
| Jun 30, 2022 | 18.13 Mn |
| Mar 31, 2022 | 15.54 Mn |
| Dec 31, 2021 | 10.08 Mn |
| Sep 30, 2021 | 8.26 Mn |
| Jun 30, 2021 | 11.19 Mn |
| Mar 31, 2021 | 7.57 Mn |
| Dec 31, 2020 | 5.68 Mn |
| Sep 30, 2020 | 3.27 Mn |
| Jun 30, 2020 | 4.44 Mn |
| Mar 31, 2020 | 3.93 Mn |
| Dec 31, 2019 | 5.30 Mn |